The rest of this guide covers why levels differ so much between people, why ancestry matters, why the test is usually ordered once, how the two reporting units compare, what a high reading may reflect, and what is worth raising with a clinician.
Lipoprotein (a), usually written Lp(a), is an LDL-like particle in which a large protein called apolipoprotein(a) is covalently attached to the apolipoprotein B-100 of an LDL particle 1. The measurement is a simple blood draw, ordered as its own line item rather than being part of a routine cholesterol panel, and most laboratory methods do not require fasting. Results come back as a concentration in either mass units or particle units.
The full detail on what the marker measures, how the sample is handled and how a result is reported sits on the Lipoprotein (a) marker page. This guide stays with the question people ask first, which is whether everyone carries the particle at all and why one person's number looks nothing like another's.
In practice, yes. The gene that codes for apolipoprotein(a) is present in essentially all people, so the particle is assembled and circulates in the blood of almost everyone, the same way LDL and HDL particles do. There is no version of normal human physiology in which the particle is simply absent by design.
What varies, enormously, is concentration. Research suggests that plasma levels differ widely from person to person and that the difference is driven mainly by inherited variation rather than by day-to-day living 2. At one end of that spread, some people sit so low that a routine assay reports the result as below the limit of detection. That is not the same as having none. It means the concentration is below the lowest value the method can reliably quantify, which is a statement about the assay as much as about the person.
At the other end, some people carry many times the population median, again without symptoms and without anything in their diet or training history to explain it. This is the practical reason the question matters. Because a high level produces no sensation, no visible sign and no abnormality on a standard cholesterol panel, the only way to know where a person sits is to measure it directly.
The difference is mostly genetic, and it traces back to one gene. Research suggests that circulating concentrations are determined largely by variation at the LPA gene, including the number of repeated segments known as kringle IV type 2 repeats, with a greater number of repeats generally corresponding to a lower plasma concentration 1.
The mechanics are worth understanding because they explain the spread. The apolipoprotein(a) protein comes in different sizes depending on how many of those repeats a person inherits. A larger protein takes longer to fold and assemble inside the liver cell, so less of the finished particle is released into the circulation. A smaller protein is produced and secreted more readily, so blood concentrations run higher. Because a person inherits one copy of the gene from each parent, the measured level reflects the combined output of two independently inherited versions.
That size-to-concentration relationship, along with other inherited variants at the same locus, accounts for most of the between-person variation 3. The practical consequence is that a high reading is not a report card on behaviour. Two people with the same body composition, the same training load and the same eating pattern can return results at opposite ends of the range, and neither did anything to earn it.
It is largely inherited, and in most adults it stays close to the same value over time. Concentrations are established early in life and are regarded in clinical consensus guidance as relatively stable through adulthood, which is the basis for the position that a single measurement is usually informative for the long term 4.
That stability makes the marker unusual. Many blood markers are snapshots. Triglycerides move with the last few meals, glucose moves within the hour, inflammatory markers move with a cold. Lipoprotein (a) behaves more like a fixed characteristic, closer to a blood group than to a fasting glucose. A result from one decade is still broadly informative in the next.
Stability is not the same as absolute constancy. Readings can shift modestly with physiological state and with the particular laboratory method used, so an isolated value that looks out of step with expectation can reasonably be rechecked. But the overall picture is one of a number that sits where inheritance put it. This also explains why family information is useful context. Because the level is passed down, a parent, sibling or child with a notably high value raises the prior probability that others in the family sit high too, which is a point worth raising with a clinician rather than something to conclude alone.
Yes, and the difference is substantial enough that it shapes how a result should be interpreted. Studies indicate that median lipoprotein (a) concentrations differ between ethnic and ancestry groups, with higher median levels reported in people of African ancestry than in several other population groups 5.
This follows directly from the genetics. Because concentration tracks inherited variation at a single locus, and because the frequency of the relevant variants differs between populations, the whole distribution shifts rather than just a few individuals within it. A value that sits at the median in one population may sit well above the median in another.
Two practical points follow. First, a single population-wide cut-off is a blunt instrument when the underlying distribution differs by ancestry, and guidance in this area continues to be refined 5. Second, a reader comparing their number against a friend's, or against a figure quoted in an article, is often comparing across different underlying distributions. This is one more reason the number belongs in a conversation with a clinician who can weigh it alongside family history, the rest of the lipid picture and overall cardiovascular risk, rather than being read as a standalone score.
Because the value is largely fixed, repeat testing adds little for most people. The case for measuring lipoprotein (a) at least once in adult life, rather than tracking it repeatedly, has been set out in clinical consensus guidance on the grounds that the concentration is genetically determined and stable 4, and European consensus guidance similarly supports measurement at least once in every adult's lifetime 6.
That framing changes how the test should be used. Most biomarkers earn their place by being repeated, because the trend carries the information. Fasting glucose, blood pressure and triglycerides are all more useful as a series than as a point. Lipoprotein (a) is the opposite. One accurate measurement tells a person something durable about their inherited cardiovascular risk profile, and that information then sits in the background of every future risk discussion.
There are sensible exceptions to a strict once-only rule. A result measured years ago with an older or different assay may be worth confirming, because methods and reporting units are not interchangeable 4. A result that looks inconsistent with family history may also be worth repeating. And where any specific intervention aimed at the marker is being considered, a clinician decides what monitoring, if any, is appropriate. The default, though, is that this is a test to get done properly once rather than annually.
Because there are two legitimate ways to quantify the same particle. Mass units (mg/dL) report how much lipoprotein (a) material is present by weight. Particle units (nmol/L) report how many particles are present. Those are different questions, and a result in one unit cannot be converted into the other with a single reliable multiplier, because the weight of each particle depends on the inherited size of the apolipoprotein(a) protein, which differs between people 4.
| Unit | What it quantifies | Why it matters |
|---|---|---|
| mg/dL (mass) | Total weight of lipoprotein (a) material per volume of blood | Widely reported and familiar, but affected by particle size differences between people |
| nmol/L (particle number) | Number of lipoprotein (a) particles per volume of blood | Counts particles directly, so it is less influenced by how large each person's apolipoprotein(a) protein is |
The second thing a reader wants is a yardstick. Below is how the marker is commonly reported in mass units.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Lipoprotein (a) | 0 to 30 mg/dL | 0 to 14 mg/dL |
These are typical lab reference ranges, and reference ranges vary by laboratory, age and sex. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and no single value defines a person's cardiovascular risk on its own. Always read a result against the range printed on your own report, in the units your own laboratory used.
A higher result suggests a higher inherited contribution to long-term cardiovascular risk, not a diagnosis. An elevated lipoprotein (a) concentration is associated with atherosclerotic cardiovascular disease, and clinical consensus guidance regards the relationship as causal rather than incidental 2. European consensus guidance describes elevated levels as a common and independent contributor to that risk, and has used a threshold in the region of 50 mg/dL (roughly 125 nmol/L) as the point above which risk begins to rise meaningfully, with around one in five people estimated to sit above it 6.
Read the result in three steps. The observation is a number above the standard reference range, which is a suboptimal finding rather than an emergency. What it may reflect is an inherited tendency that has been present since childhood and that adds to whatever other risk factors are in play, including blood pressure, apolipoprotein B, smoking status, glucose control and family history. The next step is to bring the number to a clinician, who can place it in a full risk assessment and decide whether anything about overall risk management should change.
What a high reading does not mean is that an event is coming. Risk is probabilistic and cumulative across many factors, and a single marker, however well established, does not predict an individual outcome. A result that sits well above the standard range, particularly alongside a strong family history of early cardiovascular disease, is worth discussing with a clinician promptly rather than at some undefined future appointment.
Yes, the valve is part of the picture. Elevated lipoprotein (a) is associated with calcific aortic valve stenosis, a narrowing of the aortic valve driven by progressive calcification, and European consensus guidance treats that association alongside the arterial one 6.
This is one reason the marker gets attention out of proportion to its small line on a lab report. Most of the familiar lipid markers are discussed almost entirely in terms of arteries. Lipoprotein (a) carries a second association with a structural valve condition that tends to be diagnosed late, because it develops slowly and produces symptoms only once narrowing becomes significant.
For a reader, the practical implication is modest but real. A high result is a reason for a clinician to hold both the arterial and the valvular picture in mind over the following decades, and to decide whether anything in routine follow-up should be adjusted. It is not a reason to seek imaging on your own initiative, and it is certainly not a reason to assume a valve problem exists. The honest framing is that an elevated number shifts a probability over a long horizon, and the person best placed to act on that shift is a clinician who knows the rest of your history.
There is no recognised lower limit below which a lipoprotein (a) result becomes a problem. Laboratory reference ranges for this marker start at zero, which is unusual among blood markers and reflects how the measurement is used. The question being asked is whether the concentration is high enough to add to cardiovascular risk, not whether it falls within a narrow therapeutic window the way sodium, potassium or thyroid markers do.
So a result reported as low, or as below the limit of detection, is read as a favourable finding on that one axis. It means the particle is not contributing meaningfully to the risk picture. It does not mean the particle is absent from the body, and it does not mean the cardiovascular picture overall is reassuring, because everything else still counts. A person with an undetectable lipoprotein (a) can still have raised apolipoprotein B, raised blood pressure, poor glucose control or a significant family history.
The mirror-image mistake is also worth naming. Some people with a low result conclude they have been cleared and stop paying attention to the markers that do move with daily behaviour. The more useful reading is narrower. One inherited risk contributor is low, that information is durable, and attention now belongs to the parts of the picture that can be influenced and that a clinician can help prioritise.
Because it is not one of the measurements a standard panel performs. A routine lipid panel reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Lipoprotein (a) is a separate assay that has to be requested specifically, which is why many people reach middle age with a long history of normal cholesterol results and no idea where their lipoprotein (a) sits.
There is a subtler issue as well. The cholesterol carried inside lipoprotein (a) particles is counted within the LDL cholesterol value reported on a standard panel, so LDL-C does not separate the two, and consensus guidance has highlighted this overlap when interpreting results 6. In someone with a high lipoprotein (a), part of what looks like LDL cholesterol is actually lipoprotein (a) cholesterol. Conversely, a person can have an entirely unremarkable LDL cholesterol and still carry a high lipoprotein (a) concentration, because the contribution is diluted within a larger total.
The takeaway is simple. A clean cholesterol panel is not a sign that lipoprotein (a) is low. The only way to know is to order the specific test, which is why broad testing programmes, including memberships built around repeat biomarker panels, tend to include it rather than leaving it to be requested after a problem has already appeared.
Lipoprotein (a) is most useful when read next to the rest of the lipid and cardiometabolic picture, because it describes one inherited contributor rather than total risk. The markers that commonly sit alongside it include the following.
Apolipoprotein B counts the number of atherogenic particles in circulation, since each of those particles carries a single apoB molecule, which makes it a particle count rather than a cholesterol weight. LDL cholesterol and non-HDL cholesterol describe the cholesterol load being carried by those particles. Triglycerides and HDL cholesterol add metabolic context. High sensitivity C-reactive protein is a marker of low grade inflammation. Blood pressure, fasting glucose or HbA1c and a careful family history complete the picture that a clinician uses when weighing cardiovascular risk.
Seeing these together changes how a lipoprotein (a) result reads. A high value in someone whose other markers are otherwise favourable is a different conversation from the same value in someone with several markers outside range at once, and both are different again from the same value in someone with a parent who had a cardiac event before the age of 55. Testing programmes that cover many markers at the same time exist partly for this reason. A single number read in isolation invites both false alarm and false reassurance, while a full panel lets a clinician see which contributors are fixed and which are movable.
Less than most people expect, which is the single most important thing to understand about this marker. Because the concentration is set mainly by inherited variation at one gene 1, the everyday levers that shift triglycerides or HDL cholesterol within weeks do not shift lipoprotein (a) in the same way.
Methods differ between laboratories, they report in different units, and they are not interchangeable, which is why a result should always be read against the reference range and units printed on the same report 4. Comparing a mg/dL result from one laboratory with a nmol/L result from another, or with a figure quoted in an article, is a common source of unnecessary worry.
What this means in practice is that an unexpected result is best interpreted with the laboratory report in hand rather than from memory, and that any question about whether the marker itself can or should be influenced is a clinical question. A licensed provider evaluates what, if anything, is appropriate for an individual, and that decision belongs in a consultation rather than in a search result.
Broad measurement at least once in adult life is supported by European consensus guidance, on the basis that the result is durable and identifies a risk contributor that is otherwise invisible 6. Other consensus guidance has argued for a more targeted approach, highlighting groups in which measurement is particularly informative, including people with a personal or family history of premature cardiovascular disease, people with a family history of raised lipoprotein (a), people with familial hypercholesterolaemia and people whose calculated risk sits near a decision threshold 7.
The two positions are less far apart than they look. Both rest on the same logic. The result does not change, the test is a single blood draw, and the information is most valuable early, while there are still decades in which it can inform how aggressively other risk factors are addressed.
If a family member already has a known high level, that is a particularly strong reason to ask. Because the trait is inherited, a high value in one relative raises the likelihood of high values in first degree relatives, and identifying that pattern across a family is far more informative than any individual number read alone. In a labs-first membership such as FitScript's, where 150+ biomarkers are tested per year, this marker sits within the wider panel and results are interpreted alongside everything else rather than in isolation.
Bring the actual report, with the number, the units and the laboratory's own reference range, rather than a remembered figure. The useful conversation covers four things. What the value is in context of the reporting units. What else in the lipid and cardiometabolic picture sits outside range. What the family history looks like, including any cardiovascular events before the age of 55 in men or 65 in women. And what, if anything, should change in how overall risk is managed over the coming years.
Keep the framing honest in both directions. A result above the standard reference range is a suboptimal finding that adds to a risk picture, not a diagnosis and not a prediction. A result within range removes one contributor from consideration and leaves the rest of the picture untouched. Neither result should be acted on alone, and no abnormal result should be ignored. A value well above the standard range, especially alongside a strong family history, is worth discussing with a clinician promptly.
Any question about whether a specific intervention is appropriate belongs to a licensed provider who has reviewed your full history, examination findings and complete laboratory picture. This article is educational and is not medical advice, and you should discuss your own results and any next step with a clinician or licensed provider before acting on them.
Two related pages go deeper. The Lipoprotein (a) marker page covers what the test measures, how it is run and how results are reported, and the guide to lipoprotein(a) covers the questions people ask once a result comes back above the standard range.
Essentially yes. The gene that produces the particle is present in almost all people, so the particle circulates in almost everyone. What varies enormously is the concentration, which is why the useful question is how much a person has rather than whether they have any at all.
No. Reference ranges for this marker start at zero, and there is no recognised lower limit below which a result becomes a concern. A result reported as below the limit of detection simply means the concentration is lower than the assay can reliably measure, which is a favourable finding on that one axis.
For most people, once is enough. The level is largely inherited and stays close to the same value through adult life. A repeat can make sense if the original result was measured years ago with a different method, if the value looks inconsistent with family history, or if a clinician asks for confirmation.
Most laboratory methods for this marker do not require fasting. However, it is often drawn at the same time as a full lipid panel, and the other tests in that panel may have their own instructions. Follow whatever the ordering clinician or the laboratory tells you for the full set of tests.
Laboratories use two different ways of quantifying the same particle. One reports the weight of material present, the other counts the number of particles. They cannot be converted into one another with a single reliable multiplier, so always read your number against the units and the reference range printed on your own report.
No. A single value does not predict an individual outcome and is not a diagnosis. A higher number adds one inherited contributor to a broader risk picture that also includes blood pressure, other lipid markers, glucose control, smoking status and family history. A clinician weighs all of it together.
The trait is passed down, so a high value in one family member raises the likelihood of high values in close relatives. Whether and when a family member should be tested is a decision for their own clinician, who can take their age and full history into account.
No. A routine panel reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. This marker is a separate assay that has to be ordered specifically, which is why many people with a long history of normal cholesterol results have never had it measured.
Take the printed report, with the number, the units and the laboratory's reference range, to a clinician and discuss it alongside your other markers and your family history. A value well above the standard range, particularly with a family history of early heart disease, is worth raising promptly. A licensed provider decides on any next step.